Destiny Pharma PLC
LSE:DEST
Destiny Pharma PLC
LSE:DEST
Price:
18.25 GBX
2.82%
Market Closed
Updated:
May 2, 2024
Destiny Pharma PLC
Operating Income
|
Destiny Pharma PLC
Operating Income Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Destiny Pharma PLC
LSE:DEST
|
Operating Income
-£7.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Operating Income
-$171.3m
|
CAGR 3-Years
-154%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Operating Income
-$175.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Income
-$189.4m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£59.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£53m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
See Also
What is Destiny Pharma PLC's Operating Income?
Operating Income
-7.2m
GBP
-7.2m
GBP
Based on the financial report for Jun 30, 2023, Destiny Pharma PLC's Operating Income amounts to -7.2m GBP.
What is Destiny Pharma PLC's Operating Income growth rate?
Operating Income CAGR 3Y
-6%
-6%
Over the last year, the Operating Income growth was -1%. The average annual Operating Income growth rates for Destiny Pharma PLC have been -6% over the past three years .
You don't have any saved screeners yet
